Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management

54:23
 
Share
 

Manage episode 506727289 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring an interview with Dr Neel Pasricha, including the following topics:

  • Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00)
  • Association of corneal toxicities with ADCs (4:56)
  • Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02)
  • Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44)
  • Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55)
  • Other ocular toxicities associated with cancer therapies (24:26)
  • Prevention and management of corneal toxicity (33:58)
  • Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39)
  • General clinical pearls on the management of ocular toxicities with cancer therapies (48:04)

CME information and select publications

  continue reading

969 episodes

Artwork
iconShare
 
Manage episode 506727289 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring an interview with Dr Neel Pasricha, including the following topics:

  • Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00)
  • Association of corneal toxicities with ADCs (4:56)
  • Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02)
  • Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44)
  • Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55)
  • Other ocular toxicities associated with cancer therapies (24:26)
  • Prevention and management of corneal toxicity (33:58)
  • Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39)
  • General clinical pearls on the management of ocular toxicities with cancer therapies (48:04)

CME information and select publications

  continue reading

969 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play